Unravelling glioblastoma’s secrets and harnessing two decades of progress

From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress

https://www.nature.com/articles/s41392-023-01637-8

Paxalisib (GDC-0084) is a brain-penetrant PI3K/mTOR inhibitor that potently inhibits AKT phosphorylation and reduces orthotopic tumour growth in vivo.285,286 Paxalisib is currently in phase I/II clinical trials for both newly diagnosed and progressive/recurrent glioblastoma in adults (NCT03522298, NCT01547546) and children (NCT05009992) with encouraging preliminary results.